Vijaya Diagnostic Centre Limited has informed the Exchange regarding Change in Director(s) of the company.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre's board, meeting on February 13, 2026, approved the unaudited Q3 FY26 financial results (details not shared in this filing). Mr. S. Ramachandra Reddy stepped down as CFO due to internal restructuring, but continues as General Manager – Finance & Accounts, signalling a smooth transition. The board appointed Mr. Ankit Shah (ex-Group CFO of Incor/OMNI Hospitals, a Chartered Accountant with two decades of finance experience) as the new CFO, along with Mr. Sai Prasad (ex-Optum/UnitedHealth) as CTO and Mr. Venkata Siva Rama Raju Vegesna (returning from KIMS Hospitals) as COO. Two new Non-Executive Independent Directors — senior advocate Mr. Ravi Shankararamiah and gynaecologist Dr. Sasikala Paruchuri Kola — were appointed for 5-year terms, subject to shareholder approval. The company also granted 1,15,000 ESOPs at ₹809 per option (a 20% discount to the 3-month average price) under its 2018 plan, and revised its Related Party Transaction policy to align with the latest SEBI framework.
A significant leadership overhaul at the C-suite level, bringing in external healthcare-finance and technology talent, which may be viewed positively for professionalisation but could also raise short-term execution risk. The outgoing CFO's continued role in finance minimises disruption, while the ESOP grant at a discount and strengthened board independence should support investor confidence.